
Oral Berotralstat Expanded Access Program
Hereditary AngioedemaHAE1 moreThis expanded access program will provide access to berotralstat for eligible participants with hereditary angioedema in the U.S.

MAP to Provide Access to Ruxolitinib, for Patients With PMF or PPV MF or PET-MF
Primary Myelofibrosis (PMF)Post Polycythemia Myelofibrosis (PPV MF)1 moreThe purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with PMF, PPV MF or PET MF. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations. The requesting Treating Physician submitted a request for access to drug (often referred to as Compassionate Use) to Novartis which was reviewed and approved by the medical team experienced with the drug and indication.

Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small...
CarcinomaNon-Small Cell Lung3 moreThe purpose of this Managed Access Program (MAP) Cohort Treatment Plan is to provide guidance to the Physician for the treatment and monitoring of patients in the Cohort MAP. The Physician should follow the suggested treatment guidelines. Furthermore, the Physician must comply with the MAP Agreement Letter and applicable local laws and regulations.

Individual Patient Compassionate Use of Mirdametinib
Neurofibromatosis Type 1-Associated Plexiform NeurofibromasHistiocytic Neoplasm1 moreThis program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.

CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.

Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus...
System; Lupus ErythematosusThis protocol is part of an FDA Individual Patient Expanded Access IND. This study is to be conducted according to US and International Standards of Good Clinical Practice (FDA Title 21 part 312 and International Conference on Harmonization guidelines), applicable government regulations and Hope Biosciences Stem Cell Research Foundation policies and procedures.

Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR...
Intrahepatic CholangiocarcinomaBasilea is providing expanded access to derazantinib for patients with locally advanced, inoperable or metastatic intrahepatic cholangiocarcinoma (iCCA) with FGFR genomic alterations on a patient by patient basis while clinical development of derazantinib is ongoing.

Study on Nation-wide Health Care Quality Information Openness and Transparency Mechanism Establishment...
Valuable Suggestions to Improve Health Care Quality Transparent and Accessible Medical CareResearch objectives To provide people with sufficient information regarding health care and to improve its quality, this research endeavors to discuss the establishment of a health care information openness and transparency mechanism within the framework of the National Health Insurance system. This research also evaluates whether the transparency of health care quality information makes care givers provide better quality. Meanwhile, when appropriate information and quality index are presented to patients, patients shall have more knowledge about what they are dealing with, hence less misunderstanding between hospitals and patients would occur. Research Methods To revise indicators based on international trends, related literature and the need of people. To present 50 sets of quality indicator statistically on the website, and provide updated information about the first 10 sets. To analyze and explain the outcome and purposes of the indicator to the public. To estimate the possible trend for the coming year, and provide adaptive strategy. To promote the website, and hold workshops in all six regions of Taiwan. To make the website linked to the top 5 most populated official and unofficial websites. To respond to questions on the forum of the website daily, and maintain the system, update the website regularly. To complete the acceptability survey on health care institutions and people.

Progressive Keratoconus or Ectasia Treatment Plan
KeratoconusEctasiaKeratoconus and pellucid marginal degenerations are genetically based ocular conditions and post surgical ectasia is an iatrogenic condition. These diseases are characterized by weakening of the front part of the eye that causes thinning and distortion. This distortion results in unevenness of the cornea and produces progressive near-sightedness and irregularity, which causes loss of vision when using eyeglasses. When eyeglasses fail to give enough vision, the the investigators use rigid contact lenses to create an artificial front eye surface. This improves visual acuity in many patients although they eventually fail either because they cannot be tolerated or the surface irregularity has become so severe that they are rejected. At this stage there is usually thinning and loss of clarity of the eye. There has been no treatment for this other than corneal transplantation, a complex surgical procedure with a significant complication rate and a delay in visual recovery. The treatment the investigators wish to perform strengthens the front of the eye by a chemical reaction using light and riboflavin. This technique has been studied over a decade and is widely used throughout the world. The FDA approved multicenter American clinical study is being analyzed in anticipation of its submission to the FDA for PreMarket approval. Because this is a progressive condition, the investigators wish to be able to offer this on a limited basis to patients in need with vision loss. Any treatment that can delay or prevent corneal transplantation is of great benefit. The investigators believe the evidence is compelling that this treatment is the sole alternative to surgical transplantation.

Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host...
Graft-Versus-Host DiseaseThis protocol allows for the treatment of patients, male and female, between the ages of 18 years and 70 years. Patients must have failed to respond to steroid treatment for Grade C-D acute GVHD.